1YBottom 25% of the group
Rank 61 of 63 funds
Return +5.03%
1Y returns of 63 funds in the Health Care group, sorted from highest to lowest. This fund ranks 61No. 1 is SCBGENOME(SSFE) +70.85%
DAOL GLOBAL INNOVATIVE HEALTHCARE FUND
Shows where this fund stands in its group. Not investment advice · Data as of 10 Nov 2026
DAOL-GIHEALTH invests through the master fund Janus Henderson Horizon Biotechnology Fund 93.33%
This fundDAOL-GIHEALTH
The fund that actually investsJanus Henderson Horizon Biotechnology FundThis fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Gilead Sciences GILD4.79%
Revolution Medicines RVMD4.28%Data as of 30 Sep 2026 · Top 6 shown, the rest grouped as Other · per Janus Henderson fact sheet
Over the past year it was in the bottom 25% of its group; over 5 years it returned −10.39% per year (Bottom 25% of the group)
No. 1 is SCBGENOME(SSFE) +70.85%
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 10 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | 3Y | 5Y | MAX |
|---|---|---|---|---|---|---|---|---|---|
| +1.72% | +1.84% | +6.49% | +4.97% | −4.64% | +7.60% | +5.06% | −0.16% | −42.23% | −36.34% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan |
|---|
Largest drawdown in the selected period −60.36% Previous peak 9 Feb 2021 (NAV 14.3305) → Trough 24 Mar 2026 (NAV 5.6800) · Not back to the previous peak as of 9 Nov 2026
Currently −55.61% from the peak NAV of 14.3305 (9 Feb 2021)
Over 5 years, DAOL-GIHEALTH returned -0.58 per unit of volatility, ranking 32 of 33 funds · The highest is FP HCARE-A (0.45)
กองทุนเน้นลงทุนในหน่วยลงทุนของ Janus Henderson Horizon Biotechnology Fund (กองทุนหลัก) Class IU2 ในสกุลเงินดอลลาร์สหรัฐ (USD) เพียงกองทุนเดียว โดยเฉลี่ยในรอบปีบัญชีไม่น้อยกว่าร้อยละ 80 ของมูลค่าทรัพย์สินสุทธิของกองทุน ทั้งนี้ กองทุนหลักบริหารจัดการโดย Janus Henderson Investors Europe S.A.… Its largest holdings are JAN HND HRZN BIOTECH-IU2 USD 93.33% (fact sheet 30 Sep 2026)
Risk level 7 of 8 (High risk). Since 28 May 2020, its NAV has fallen as much as −60.36% from its peak.
Actual total expense ratio (TER) 2.32% a year, against a ceiling of 6.42%. Management fee 1.61%. Front-end fee 1.61%. Back-end fee 0.00%. (Fact sheet 1 Sep 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Minimum first purchase 1 THB, subsequent purchases 1 THB. Buy orders accepted until 15:00, sell orders until 15:00, and redemption proceeds are paid T+4
Hedged at the manager's discretion. As of 30 Sep 2026, 77.55% of the value of its foreign investments was hedged
Warning Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
argenx ARGX4.28%
Praxis Precision PRAX3.71%
Travere Therapeutics TVTX3.61%
BridgeBio Pharma BBIO3.51%
Vertex Pharmaceuticals VRTX3.48%
Madrigal Pharmaceuticals MDGL2.99%
Vaxcyte PCVX2.95%
Insmed INSM2.88%Gilead Sciences GILDA US drug company making HIV treatment and prevention drugs, hepatitis drugs and cancer drugs
Revolution Medicines RVMDBiotech company that develops drugs for RAS-driven cancers, such as pancreatic cancer
argenx ARGXEuropean biotech that makes Vyvgart to treat autoimmune diseases such as myasthenia gravis
Praxis Precision PRAXBiotech company that develops drugs for neurological conditions such as epilepsy and tremor
Travere Therapeutics TVTXDevelops drugs for rare diseases, including Filspari for IgA nephropathy
BridgeBio Pharma BBIODevelops drugs for genetic diseases, including Attruby for the heart disease ATTR-CM
Makes cystic fibrosis drugs and a gene-editing therapy for thalassaemia
Hospitals, medicines and medical equipment
Vaxcyte PCVXUS company developing vaccines against pneumococcal bacteria that cause pneumonia, covering more strains
Insmed INSMHospitals, medicines and medical equipment
Based on the master fund's share of this fund's value (93.33% as of 30 Sep 2026) × each stock's weight in the master fund · stocks as of 30 Sep 2026 · fact sheet from Janus Henderson · Illustrations are for explanation only, not individual stock recommendations
No. 1 is SCBGENOME(E) +24.65% per year
No. 1 is FP HCARE-A +6.97% per year
| Feb |
|---|
| Mar |
|---|
| Apr |
|---|
| May |
|---|
| Jun |
|---|
| Jul |
|---|
| Aug |
|---|
| Sep |
|---|
| Oct |
|---|
| Nov |
|---|
| Dec |
|---|
| Full year |
|---|
| 2026 | −1.4 | −1.4 | −2.9 | +0.4 | +1.6 | +9.3 | −0.5 | +3.6 | −7.6 | +0.2 | +1.1 | · | +1.7* |
| 2025 | +7.3 | +0.7 | −4.5 | −3.4 | −2.6 | −0.1 | −5.0 | +4.5 | +1.4 | −0.2 | +5.8 | −2.3 | +0.8 |
| 2024 | −0.5 | +4.0 | −0.7 | −5.8 | +1.7 | +0.5 | +0.8 | +4.0 | −2.5 | −4.4 | +0.3 | −7.1 | −10.0 |
| 2023 | −0.6 | −3.3 | +1.8 | +0.6 | −4.1 | +3.1 | +2.0 | −5.9 | −3.3 | −3.5 | +3.9 | +3.9 | −5.9 |
| 2022 | −12.7 | +0.2 | +1.2 | −10.1 | −1.9 | −4.9 | +5.8 | −6.8 | −4.3 | +3.6 | +0.3 | −3.5 | −29.7 |
| Average | −0.6 | −0.7 | −2.1 | −2.4 | −1.6 | +2.2 | +0.4 | +0.2 | −3.0 | −0.7 | +1.6 | +0.7 | −12.5 |
|---|